Clinical trials: sponsored by Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT04024761
- Testing
- CIML NK, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Pediatric Cancer, CNS Tumor, Childhood
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
This research study is examining a preventive skin care regimen for children diagnosed with a brain tumor and receiving anti-cancer therapy with a MEK, Pan-RAF, or BRAF inhibitor.
- Conditions
- Pediatric Cancer, CNS Tumor, Childhood, Skin Inflammation
- Trial name
- NCT04479514
- Testing
- Warm Baths or Showers, Moisturizer, SPF 30 or Higher Suncreen
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Thyroid Cancer
Hereditary Risk Factors for Thyroid Cancer
Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes.
- Trial name
- NCT02747888
- Testing
- •Referral to Genetic Counselor, if indicated
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL)
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies.
- Conditions
- Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML)
- Trial name
- NCT02091245
- Testing
- KPT-330
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Ewing Sarcoma, Ewing Sarcoma of Bone
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.
- Conditions
- Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT06068075
- Testing
- FoundationOne Liquid CDx
- Where
- 15 sites in United States
- Volunteers
- 340 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Ductal Carcinoma
Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
The goal of this research study is to evaluate the efficacy and safety of low-dose exemestane versus low-dose tamoxifen in post-menopausal women at high risk for breast cancer.
- Conditions
- Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia
- Trial name
- BabyTEARS (NCT07499999)
- Testing
- Exemestane, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
Li-Fraumeni Syndrome, TP53 Gene Mutation
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g.
- Conditions
- Li-Fraumeni Syndrome, TP53 Gene Mutation, Hereditary Cancer Syndrome, Clonal Hematopoiesis
- Trial name
- LiFT_UP (NCT04541654)
- Testing
- Data and Specimen Collection
- Where
- 3 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Neuroblastoma
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
- Conditions
- Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
- Trial name
- NCT02909777
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Neuroblastoma, High-risk Neuroblastoma
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income…
- Trial name
- RISE in HR NBL (NCT06831552)
- Testing
- RISE Intervention
- Where
- 6 sites in United States
- Volunteers
- 84 people
- Sponsor
- Dana-Farber Cancer Institute
Li-Fraumeni Syndrome
Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes
This study is evaluating Whole Body MRI as a possible screening tool to diagnose cancer for people with LFS and other inherited cancer predisposition syndromes.
- Trial name
- NCT02950987
- Testing
- Whole Body MRI
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
Stress, Anxiety
Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer
The goal of this study is to find the best way to help participants and families manage the stress of facing a serious illness and be better able to "bounce back" or be resilient after a difficult situation.
- Trial name
- NCT06038318
- Testing
- PRISM Program Video Coach, PRISM Program Text Coach, mPRISM Program App
- Where
- 2 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma
Abemaciclib + Pembrolizumab In Glioblastoma
This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment.
- Trial name
- NCT04118036
- Testing
- Pembrolizumab, Abemaciclib
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Pediatric Acute Lymphoblastic Leukemia, Leukemia
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
The goal of this research study is to understand the acceptability and feasibility of the Sleep ALL Night intervention among children with Acute Lymphoblastic Leukemia (ALL) in hopes of improving the discussion of sleep disorders…
- Conditions
- Pediatric Acute Lymphoblastic Leukemia, Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT05866887
- Testing
- Sleep ALL Night
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Neuroblastoma, Pediatric Solid Tumor
GVAX Plus Checkpoint Blockade in Neuroblastoma
This research clinical trial is studying the creation and administration of GVAX, an irradiated GM-CSF secreting, autologous neuroblastoma cell vaccine (GVAX) in combination with nivolumab and ipilimumab as a possible treatment…
- Trial name
- NCT04239040
- Testing
- Tissue collection, GVAX vaccine, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Leukemia, Brain Tumor
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
This research study is studying a novel drug called ALRN-6924 as a possible treatment for resistant (refractory) solid tumor, brain tumor, lymphoma or leukemia.
- Conditions
- Leukemia, Brain Tumor, Solid Tumor, Lymphoma
- Trial name
- NCT03654716
- Testing
- ALRN-6924, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumor, Childhood, Lymphoma
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
Arm 1 of this research study is studying an investigational drug called BMS-986158 as a possible treatment for pediatric solid tumors or lymphoma.
- Conditions
- Solid Tumor, Childhood, Lymphoma, Brain Tumor, Pediatric
- Trial name
- NCT03936465
- Testing
- BMS-986158, BMS-986378
- Where
- 6 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Dana-Farber Cancer Institute
Other Cancer
Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention
The goal of this new intervention is to make it easier for families to meet their basic household needs during childhood cancer treatment. The investigators want to learn how to best use PediCARE to help care for families.
- Trial name
- NCT03638453
- Testing
- PediCARE, Usual Care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Bone Mineral Density, Childhood Cancer Survivors
Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
This research study is evaluating bone mineral density in childhood cancer survivors who have a history of bone fracture.
- Trial name
- NCT02355340
- Testing
- Dual energy x-ray absorptiometry (DXA), Peripheral quantitative computed tomography (pQCT)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Neuroblastoma, High-risk Neuroblastoma
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
This is a randomized Phase II trial evaluating the addition of the Pediatric Cancer Resource Equity (PediCARE) health equity intervention to usual supportive care for poverty-exposed children with newly diagnosed high-risk…
- Conditions
- Neuroblastoma, High-risk Neuroblastoma, Pediatric Cancer, Disparities
- Trial name
- NCT06335745
- Testing
- PediCARE Intervention
- Sponsor
- Dana-Farber Cancer Institute
Ewing Sarcoma, Ewing's Sarcoma Recurrent
Palbociclib + Ganitumab In Ewing Sarcoma
This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma. The names of the study drugs involved in this study are: Palbociclib Ganitumab
- Trial name
- NCT04129151
- Testing
- Palbociclib, Ganitumab
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute